Small-molecule therapies for cardiac hypertrophy: Moving beneath the cell surface

Timothy A. McKinsey, David A. Kass

Research output: Contribution to journalReview articlepeer-review

Abstract

Pathological stress from cardiovascular disease stimulates hypertrophy of heart cells, which increases the risk of cardiac morbidity and mortality. Recent evidence has indicated that inhibiting such hypertrophy could be beneficial, encouraging drug discovery and development efforts for agents that could achieve this goal. Most existing therapies that have antihypertrophic effects target outside-in signalling in cardiac cells, but their effectiveness seems limited, and so attention has recently turned to the potential of targeting intracellular signalling pathways. Here, we focus on new developments with small-molecule inhibitors of cardiac hypertrophy, summarizing both agents that have been in or are poised for clinical testing, and pathways that offer further promising potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)617-635
Number of pages19
JournalNature Reviews Drug Discovery
Volume6
Issue number8
DOIs
StatePublished - Aug 1 2007

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Small-molecule therapies for cardiac hypertrophy: Moving beneath the cell surface'. Together they form a unique fingerprint.

Cite this